MedTrace Logo

Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy

NCT00016653 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-10-27

No results posted yet for this study

Summary

This study will help to determine the effectiveness of glutamine and creatine as a possible therapy for DMD. Boys with DMD who are enrolled in this trial will be randomly chosen to receive creatine monohydrate or glutamine or an inactive placebo orally for six months. Once a month during the six-month treatment period, the study participants will have their muscle strength evaluated using manual and computerized testing methods. This study will be conducted at several CINRG Centers throughout the U.S., Belgium, Israel and Puerto Rico. This study is supported by the Muscular Dystrophy Association.

Conditions

  • Muscular Dystrophy, Duchenne

Interventions

DRUG

Glutamine

DRUG

Creatine Monohydrate

Sponsors & Collaborators

  • Cooperative International Neuromuscular Research Group

    lead NETWORK

Principal Investigators

  • Diana M Escolar, MD · Cooperative International Neuromuscular Research Group

  • Gunnar Buyse, MD, PhD · Cooperative International Neuromuscular Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
5 Years
Max Age
9 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00016653 on ClinicalTrials.gov